Home > Press > Nantero Announces Licensing to Alpha Szenszor, Inc.
Start up Developing Portable and Cost-effective Detectors for Infectious Diseases Including HIV.
Nantero Announces Licensing to Alpha Szenszor, Inc.
WOBURN, MA | Posted on June 26th, 2007
Nantero, Inc., a nanotechnology company using carbon nanotubes for the development of next-generation semiconductor devices, has provided license rights for biomedical sensors to Alpha Szenszor, Inc., a newly-formed company also based in Woburn, Massachusetts. Alpha Szenszor is developing a suite of sensor products in the medical field, including portable and cost-effective detectors for infectious diseases such as HIV. Alpha Szenszor's co-founders include Steve Lerner, an industry veteran with over 28 years of product development and industrialization experience, and Professor Charles Lieber of Harvard University, world-renowned expert in the field of nanobio sensors.
Nantero's intellectual property includes over 100 patent applications, of which over 25 have already been granted. This intellectual property portfolio is centered around the use of carbon nanotubes in mass manufacturing environments to make a variety of products, including Nantero's NRAM™, a high-density nonvolatile random access memory device. In addition to its work developing NRAM, Nantero is actively licensing its intellectual property portfolio to both startups and established companies for the development of other products that incorporate carbon nanotubes.
Alpha Szenszor is developing a biomedical sensor platform for applications in the field of disease diagnostics and personalized medicine. These products will allow testing of a wide range of diseases such as Cold and Flu, Cancer, Heart Disease, Sexually Transmitted Infections, Food Contamination, and the presence of other life threatening disorders. Alpha Szenszor technology will eliminate the costly and time consuming procedures associated with current diagnostics technology.
Steve Lerner, CEO and Co-Founder of Alpha Szenszor, said, "With our world-class team combining experts in health care, semiconductor processing, and Nantero's scalable carbon nanotube technology, we are poised to bring revolutionary products to market in a very short time frame. We will enable portable disease testing that would be available through local pharmacies and allow anyone to test themselves with total privacy and at a low cost. When placed in the hands of the primary care physicians, we envision our technology becoming part of every patient check-up."
Professor Charles Lieber, Co-Founder of Alpha Szenszor, added, "The Nantero technology provides a highly industrialized platform through which my years of work may be applied to facilitate this revolution in global health care."
Greg Schmergel, CEO and Co-Founder of Nantero noted "Nantero is approached frequently for licenses to its intellectual property for various fields of use, and we have to pick carefully the right partners who have the capability to bring products to market that will add substantial value to their customers. We believe Alpha Szenszor is such a partner and look forward to working with them."
About Nantero, Inc.
Nantero is a nanotechnology company using carbon nanotubes for the development of next-generation semiconductor devices. Nantero’s main focus is the development of NRAM™. Nantero is also working with licensees on the development of additional applications of Nantero’s core nanotube-based technology.
More information on Nantero, Inc. is available in English and Japanese at http://www.nantero.com
About Alpha Szenszor
Alpha Szenszor a point of care molecular diagnostics chip company. Alpha Szenszor’s products allow real time, label free detection and quantification of proteins and nucleic acids in a highly scaleable and cost effect platform. Most importantly the company ushers in a digital alternative to current optically based diagnostics. Alpha Szenszor is in the process of raising series A funds, and has already garnered the endorsement of several industry leaders.
For more information, please click here
Suzanne Gibbons-Neff, 617-670-1763
Alpha Szenszor Inc., 978-371-7084
Copyright © Business Wire 2007
If you have a comment, please Contact
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
NYU Researchers Break Nano Barrier to Engineer the First Protein Microfiber October 23rd, 2014
Iranian Scientists Apply Nanotechnology to Produce Surgery Suture October 23rd, 2014
RF Heating of Magnetic Nanoparticles Improves the Thawing of Cryopreserved Biomaterials October 23rd, 2014
Sopping up proteins with thermosponges: Researchers develop novel nanoparticle platform that proves effective in delivering protein-based drugs October 22nd, 2014
QuantumWise guides the semiconductor industry towards the atomic scale October 24th, 2014
SUNY Polytechnic Institute Invites the Public to Attend its Popular Statewide 'NANOvember' Series of Outreach and Educational Events October 23rd, 2014
Advancing thin film research with nanostructured AZO: Innovnano’s unique and cost-effective AZO sputtering targets for the production of transparent conducting oxides October 23rd, 2014
Strengthening thin-film bonds with ultrafast data collection October 23rd, 2014
Researchers patent a nanofluid that improves heat conductivity October 22nd, 2014
Nanodevices for clinical diagnostic with potential for the international market: The development is based on optical principles and provides precision and allows saving vital time for the patient October 15th, 2014
Aculon Receives Patent for Application of Enhanced Bonding Layers on Titanium October 9th, 2014
harmaEngine will join Nanobiotix’ pivotal trial for NBTXR3 in Soft Tissue Sarcoma to accelerate its development in Asia-Pacific: PharmaEngine to make milestone payment to Nanobiotix in October 2014 to recognize the value created October 8th, 2014